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Abstract
Background: Neuropathy often occurs following drug treatment such as chemotherapy. Severe instances of
neuropathy can result in cessation of life-saving chemotherapy treatment.
Results: To support data representation and analysis of drug-associated neuropathy adverse events (AEs), we
developed the Ontology of Drug Neuropathy Adverse Events (ODNAE). ODNAE extends the Ontology of Adverse
Events (OAE). Our combinatorial approach identified 215 US FDA-licensed small molecule drugs that induce signs
and symptoms of various types of neuropathy. ODNAE imports related drugs from the Drug Ontology (DrON) with
their chemical ingredients defined in ChEBI. ODNAE includes 139 drug mechanisms of action from NDF-RT and 186
biological processes represented in the Gene Ontology (GO). In total ODNAE contains 1579 terms. Our analysis of
the ODNAE knowledge base shows neuropathy-inducing drugs classified under specific molecular entity groups,
especially carbon, pnictogen, chalcogen, and heterocyclic compounds. The carbon drug group includes 127 organic
chemical drugs. Thirty nine receptor agonist and antagonist terms were identified, including 4 pairs (31 drugs)
of agonists and antagonists that share targets (e.g., adrenergic receptor, dopamine, serotonin, and sex hormone
receptor). Many drugs regulate neurological system processes (e.g., negative regulation of dopamine or serotonin
uptake). SPARQL scripts were used to query the ODNAE ontology knowledge base.
Conclusions: ODNAE is an effective platform for building a drug-induced neuropathy knowledge base and for
analyzing the underlying mechanisms of drug-induced neuropathy. The ODNAE-based methods used in this study
can also be extended to the representation and study of other categories of adverse events.
Background
The word “neuropathy” is derived from two parts:
“neuro” referring to the nerve and “pathy” indicating dis-
ease. Neuropathy refers herein to nerve damaging. The
manifestation of neuropathy often includes chronic pain,
loss of sensation, paresthesia, dysesthesia, and motor
movement disorders [1]. Drug-induced neuropathies are
usually uncommon (2–4 % of cases in one outpatient
neurology setting), but crucial to recognize because
intervention can lead to significant improvement or
symptom resolution [2]. Typically, chemotherapy drugs
cause higher incidences of severe neuropathy than other
drugs. For example, bortezomib (indicated for multiple
myeloma and mantle cell lymphoma) caused treatment-
related severe peripheral neuropathy (PN) (grade 3–4)
in ~35 % of 331 relapsed multiple myeloma patients
(Drugs@FDA). Besides affecting patient quality of life,
an effective treatment could be discontinued if PN is
intolerable. The signs, symptoms and severity of
drug-induced neuropathy are related to many vari-
ables such as mechanism of drug action, drug dose,
duration of treatment, and host factors. Drug targets
in the nervous system are diverse and include cell
bodies in the dorsal root ganglia, ion channels, myelin
sheath, and neuronal mitochondria. These neurotoxic tar-
gets often overlap with drug therapeutic mechanisms. For
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example, taxanes, which interfere with cell division and
apoptosis by binding to β-tubulin subunits, can disrupt
axonal transport in neurons and eventually lead to axono-
pathy. While therapeutic strategies to alleviate neuropathy
exist, a better understanding of pathophysiological mecha-
nisms of the drug-induced neurotoxicity is needed to aid
the development of novel chemotherapeutics with a lower
neurotoxic profile.
The study of drug-associated neuropathy adverse
events (AEs) relies on the use of different ontologies.
Biomedical ontologies are sets of terms and relations
that represent entities in the scientific world and how
they relate to each other. Ontologies have been used in
applications such as the establishment of knowledge
base and computer-assisted automated reasoning.
The Ontology of Adverse Events (OAE; http://
www.oae-ontology.org/) is a community-based bio-
medical ontology in the domain of adverse events
[3]. OAE provides a logically defined terminology
and term relations for various adverse events, in-
cluding different types of neuropathy adverse events.
OAE, together with related theories, also provides a
semantic framework that links clinical adverse event
phenotypes with underlying biological mechanisms
[4, 5]. Drug Ontology (DrON) is a newly generated
ontology of drugs and related drug information [6].
DrON incorporates drug information from RxNorm,
a normalized drug naming system provided by the
National Library of Medicine at NIH [7]. DrON also
links drugs to chemical names based on chemical
nomenclature as represented in Chemical Entities of
Biological Interest (ChEBI) [8]. NDF-RT is another
ontology that includes mechanisms of action for
drugs. The mechanisms of actions may be linked to
Biological Processes, a part of the Gene Ontology
(GO) [9]. All these ontologies provide the basis for
interdisciplinary study, representation, and analysis
of neuropathy adverse events.
By integrating these ontologies with known drug-
associated neuropathy AEs, it is possible to generate a
domain-specific ontology to represent and study drug-
associated neuropathy AEs. In this paper, we report our
efforts in developing a community-driven Ontology of
Drug Neuropathy Adverse Events (ODNAE). We col-
lected neuropathy-inducing drugs from a number of
datasets, ontologically represented the drugs and their
mechanisms, and generated scientific insights using
ontology-based approaches.
Methods
Identification of FDA-approved drugs with neuropathy in
their labels
Several methods were applied to identify the US Food
and Drug Administration (FDA)-approved drugs known
to cause neuropathy. First, our study included a list of
neuropathy-associated drugs identified from a previous
study using literature mining, survey of three databases
(Drugs@FDA, DailyMed, and SIDER), and manual cur-
ation [10]. This study uses neuropathy related terms
from CTCAE [11] and MedDRA [12]. Secondly, we used
an ADEpedia dataset developed at Mayo Clinic (http://
adepedia.org) [13] to obtain the information on drugs
associated with neuropathy. In the ADEpedia dataset,
drugs are represented using the RxNorm codes (i.e.,
RxCUIs) and AEs are represented using the SNOMED
CT [14] codes. Thirdly, we searched LinkedSPLs, a
Linked Data resource that published the information
of FDA-approved drug package inserts from Dai-
lyMed [15]. Lastly, we manually reviewed all the
package insert documents and selected drugs after
manual confirmation.
ODNAE editing and existing ontology term import
ODNAE was developed using the format of W3C standard
Web Ontology Language (OWL2) (http://www.w3.org/TR/
owl-guide/). For efficient editing of OAE, Protégé 4.3 or 5.0
OWL ontology editor (http://protege.stanford.edu/) was
used. Based on the annotated data, we used OntoFox
(http://ontofox.hegroup.org/) [16] to extract subsets of re-
lated terms from different ontologies. Neuropathy AEs
from OAE and drugs from DrON, were retrieved and
imported to ODNAE, respectively. The mechanisms of
most of these drugs are extracted from NDF-RT and
imported to ODNAE. Gene Ontology (GO) biological pro-
cessing terms that match the drug mechanisms were manu-
ally identified and imported to ODNAE using OntoFox.
Given that many terms from multiple ontologies (OAE,
DrON, NDF-RT, and GO) were imported into ODNAE,
the alignment of all the imported terms was a challenge
and had been solved by a carefully designed strategy to
manually assert top level terms of these imported ontology
subsets under the ODNAE ontology hierarchical structure.
Once the top level terms are aligned, the middle and bot-
tom level ontology terms will be aligned automatically. In
addition, we used Ontorat, another internally developed
web-based program (http://ontorat.hegroup.org/) [17],
to assign RxNorm and NDF-RT identifiers to corre-
sponding DrON drug terms using the annotation
property rdfs:seeAlso.
Generation of new ODNAE terms and axioms related to
drug-induced neuropathy AEs
Ontorat was used to generate specific drug-induced
neuropathy AE terms with “ODNAE_” prefix, and define
new axioms to link the newly generated ODNAE terms
with corresponding drugs and neuropathy AEs. To run
the Ontorat program, all the related data were formal-
ized into a structure Excel template. Ontorat scripts
Guo et al. Journal of Biomedical Semantics  (2016) 7:29 Page 2 of 12
were developed to identify sets of data and insert them
into ODNAE under appropriate hierarchical structures.
ODNAE access, visualization, and licensing
The ODNAE project website is located at Github:
https://github.com/odnae. ODNAE has been deposited
in the repositories of Ontobee (http://www.ontobee.org/
ontology/ODNAE) and NCBO BioPortal (http://bio-
portal.bioontology.org/ontologies/ODNAE). The
ODNAE source code is also freely available under the
Creative Commons 3.0 License (http://creativecommon-
s.org/licenses/by/3.0/). This licensing allows ODNAE
users to freely distribute and use ODNAE.
SPARQL query of ODNAE
The Ontobee [18] SPARQL query web page (http://
www.ontobee.org/sparql) was used to perform SPARQL
queries of the ODNAE ontology to answer specifically
designed questions. In total, six files of 20 SPARQL
scripts were generated for this study. These files are
stored on the Github website: https://github.com/odnae/
odnae/tree/master/docs/SPARQL. Additional file 1 con-
tains a summary of these 20 scripts.
Heatmap analysis of ODNAE data
The correlation between drug molecular entities and ad-
verse events were presented using a heatmap. The heat-
map was created using n ×m count matrix, where n is
the number of AEs and m is the number of drug mo-
lecular entities (i.e., the top level drug chemical entity
groups). Each cell in the matrix is the number of drugs
under the drug chemical group (i.e., column) that are as-
sociated with a specific AE (i.e., the row). The matrix
was generated by first using SPARQL to obtain the raw
data of each drug chemical group, drug, and drug-
associated AEs, and using an R program to process and
transfer the data to the desired format. The heatmap
was ordered using the Manhattan distance and the mo-
lecular entities were clustered using the complete link-
age method. The heatmap was plotted using R 3.1.3.
Results
The overall goal of this project is to generate and
analyze an ontology knowledge base of drug-associated
neuropathy AEs. By “ontology knowledge base”, we
mean that the ontology itself serves as a knowledge base
that integrates various aspects of knowledge related to a
specific domain, promoting knowledge integration and
discovery. Therefore, the ODNAE serves as a knowledge
base comprising drug components, chemical entities of
active drug ingredients, drug mechanisms, and drug-
inducing neuropathy AEs. To achieve this goal, we first
used different methods to identify drugs associated with
different types of neuropathy AEs. Related information
was then represented in the ODNAE and further
analyzed.
In what follows, single quotation marks ‘’ are used to
quote specific ontology terms.
Drugs associated with neuropathy adverse events
As described in the Methods section, three methods
(i.e., literature mining followed by manual curation [10],
ADEpedia query [13], and LinkedSPLs query [15]) were
used to obtain drugs associated with neuropathy
AEs. Each of these methods identified from 150-230
neuropathy-inducing drugs. After a second round of
manual verification, we verified 215 chemical drugs
known to induce neuropathy AEs. This list of drugs
does not include 36 drugs that were originally iden-
tified from our data sources due to either a lack of
DrON IDs, a clear label of a neuropathy AE, or ab-
sence of a subclass of neuropathy AE. It is noted
that the data from user-reported FDA adverse event
case reporting systems (FAERS) [19] were not used
since the FAERS results can be quite noisy. An Excel
file containing 215 annotated drugs and neuropathy
AEs is stored in the ODNAE GitHub repository:
https://github.com/odnae/odnae/raw/master/src/ontology/
Ontorat_inputs/odnae-data-outputupdate.xlsx.
General ODNAE design and statistics
The top level hierarchy of ODNAE is demonstrated in
Fig. 1 and explained below.
First, ODNAE extends OAE and reuses the upper level
of OAE. Like OAE, ODNAE uses the Basic Formal
Ontology (BFO) [20] as the upper level ontology. BFO
contains two branches, ‘continuant’ and ‘occurrent’
[21, 22]. The ‘continuant’ branch represents time-
independent entities such as material entity and qual-
ity. The ‘occurrent’ branch represents time-related en-
tities such as adverse event, drug administration, drug
metabolism, and dose accumulation in human. By
aligning different terms under the two branches of
BFO, knowledge from broad biological areas related
to drug-associated neuropathy AEs were captured and
organized under a unified ontology-level structure.
Among several drug ontologies (RxNorm, NDF-RT,
and DrON), we selected DrON as the default ontology
for representing drugs, as DrON allows mapping be-
tween drugs and ChEBI chemical terms. In addition, like
ODNAE and OAE, DrON is also aligned with BFO. The
advantage of using BFO is that BFO has been adopted
by over 100 biomedical ontologies. All these ontologies
follow ontology design principles of the Open Biomed-
ical Ontologies (OBO) Foundry [22]. Therefore, we were
able to easily import and integrate related terms from
DrON, OAE, and other OBO ontologies into ODNAE.
In order to enable data integration and data reuse, we
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added links from the DrON terms to RxNorm and
NDF-RT IDs by annotation property rdfs:seeAlso in
ODNAE.
Figure 2 shows the basic design pattern of ODNAE
representation of drug-associated neuropathy AEs
(Fig. 2a) and one example of implementing the design
(Fig. 2b). Specifically, a ‘drug-associated neuropathy AE’
(e.g., ‘bupropion-associated neuropathy AE’) occurs after
(‘preceded_by’) an administration of a drug (e.g., Bupro-
pion Oral Tablet or Aplezin) in a ‘human’ patient. The
human has different qualities (such as ‘age’, ‘gender’, and
‘disease history’) and genomics background which may
affect adverse event outcomes. The drug has a proper
component of a molecular entity (e.g., bupropion). The
drug also has a specific role in a biological process. The
NDF-RT mechanism of action (MoA) terms (e.g.,
dopamine uptake inhibitor) is represented as ‘role’
(BFO_0000023), which is realized in a Gene Ontology
(GO) biological process (e.g., ‘negative regulation of
dopamine uptake’ GO_0051585) (Fig. 2).
The linked information illustrated in Fig. 2 is logically
defined in ODNAE. Logical constraints allow proper in-
tegration and hierarchies among terms from different
ontologies of drugs, the chemicals of active drug ingredi-
ents, GO processes, and other information cross-linked
with axioms. As a result, the ontology knowledge base of
drug neuropathy AEs can be analyzed at different levels
of classification.
As shown in Figs. 1 and 2, ODNAE imports terms
from many existing ontologies and also contains newly
generated, ODNAE-specific terms. In total, ODNAE
contains 1579 terms, including 249 terms with
“ODNAE_” prefix and terms imported from other on-
tologies such as 25 OAE terms, 500 ChEBI terms,
and 331 DrON terms. The detailed statistics of
ODNAE is available at the Ontobee website: http://
www.ontobee.org/ontostat/ODNAE.
In the next sections, we will provide more details
about the ODNAE contents and scientific insights from
ODNAE data analysis.
Various types of neuropathy AEs are associated with
drugs
Our study identified 20 types of neuropathy AEs, each of
which is associated with at least one drug (Fig. 3). Repre-
sented in a hierarchical structure, these AEs are logically
defined and cross-referenced to existing AE representa-
tion systems including MedDRA [12].
Ontology representation of neuropathy-associated drugs
and drug ingredients
The active ingredient of a drug product plays a vital role
in its mechanism. The chemical structures of the drug
active ingredients are represented in ODNAE using
ChEBI terms. Additional ChEBI terms are also imported
to form the hierarchy of these active ingredients of
drugs. The relation between a drug and a ChEBI chem-
ical is presented by an object property ‘has_proper_part’
(Fig. 2).
Fig. 1 Top level ODNAE hierarchy
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Most drug-associating ChEBI terms are under the branch
of ‘molecular entity’ (CHEBI_23367). There are 23 classes,
for example, ‘carbon group molecular entity’ (CHEBI_
33582), at the third layer below ChEBI term ‘molecular en-
tity’ (Fig. 4a). Among all these 23 classes, the ‘carbon group
molecular entity’ class is associated with 127 drugs (the
highest number). All drugs under this group were indeed
all organic molecular entities (Fig. 4a). Among 13 sub-
classes of organic entities, heterorganic entities link to 116
neuropathy-inducing drugs (Fig. 4a). Figure 4b provides an
example of a subclass of heterorganic entities (Fig. 4b). All
the results can be counted from the ontology display in the
Protégé OWL editor. Alternatively, as detailed later, a
SPARQL script can obtain the same count results.
Ontology-based representation and analysis of drug
mechanisms
A total of 139 mechanisms of action (MoA) terms re-
lated to neuropathy-inducing drugs was identified from
NDF-RT and imported to ODNAE. We identified 13 GO
biological processes that directly realize roles, or MoAs
from NDF-RT. Many MoA terms do not have matched
GO terms. ODNAE also includes 173 GO terms that are
the ancestor (or related) terms of these 13 GO terms.
Much insight was gained by examining the NDF-RT
MoAs collected in ODNAE (Fig. 5). All NDF-RT roles
were organized as subclasses of ‘role in cellular and mo-
lecular interactions’, including the roles as ‘enzyme in-
hibitors’, ‘immunological and biological factors’, and
receptors of different biological interactions. Our results
showed that 12 neuropathy AE related drugs inhibit the
uptake of three neurotransmitters [dopamine (1), nor-
epinephrine (10), and serotonin (11)]. There are 20
drugs that interact with the G-protein receptors that
contribute to neuropathy adverse events. We identified
39 drug agonist and antagonist terms, including 16 ago-
nists and 23 antagonists. Among them, there are four
pairs of agonists and antagonists of the same targets
Fig. 2 ODNAE design pattern and example. a ODNAE design pattern of representing drug-associated neuropathy AE. b ODNAE representing
bupropion-associated neuropathy AE
Guo et al. Journal of Biomedical Semantics  (2016) 7:29 Page 5 of 12
Fig. 3 Various drug-associated neuropathy AEs as represented in OAE and imported to ODNAE. Red numbers represent the numbers of drugs
associated with the corresponding AEs. Circled are 3 terms not asserted but inferred under ‘peripheral neuropathy AE’ using a Hermit reasoner in
Protege OWL editor
Fig. 4 Example ChEBI classification of drug chemicals inducing neuropathy AEs. a 14 neuropathy-inducing drugs are classified under nucleotide.
b 21 drugs containing organohalogen compounds as active ingredients were found to induce neuropathy AEs
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(Table 1). Specifically, there are 3 agonist drugs and 7
antagonist drugs of the adrenergic receptor, 4 agonists
and 2 antagonists of dopamine, 4 agonists and 3 antago-
nists of serotonin, and 5 agonists and 2 antagonists of
hormone receptor (Table 1). In addition, there are 3 hor-
mone receptor modulators (i.e., Leuprolide, Leuprolide
acetate, and Taxoxifen) that are also associated with
neuropathy AE (Table 1).
The GO terms in ODNAE cover a variety of processes,
including negative regulation of neurotransmitter uptake
and synaptic transmission. GO terms are linked to genes
and proteins. We will investigate in the future how
ODNAE can represent gene/protein-based neuropathy
mechanisms with the support of GO.
Query of drug-induced neuropathy AEs
The ODNAE knowledge base can be queried through the
Ontobee SPARQL program. Different questions can be
addressed using SPARQL queries. For example, a SPARQL
script was generated to identify what drugs act as a sero-
tonin agonist (Fig. 6). The query resulted in four drugs:
eletriptan, almotriptan, sumatriptan, and zolmitriptan.
In addition to the query shown in Fig. 6, many other
SPARQL scripts were also generated to meet different
requirements for many studies introduced in this article,
we have generated many SPARQL scripts. All these
query scripts have been collected and provided in the
Additional file 1.
Heatmap analysis of the correlations between drug
molecular entities and neuropathy AEs
One question is how to correlate the drug molecular en-
tity group with specific neuropathy AEs. To address this
question, a heatmap analysis was performed (Fig. 7). The
data for the heatmap analysis was achieved using SPARQL
in the Methods section. The data obtained from SPARQL
queries include the drug molecular entities and AEs that
are associated with different drugs in ODNAE. The heat-
map explores the relation between drug molecular entities
and various neuropathy AEs (Fig. 7).
Fig. 5 Various roles in cellular and molecular interactions played by
drugs associated with neuropathy AEs. The branch circled in blue
indicates inhibitor roles related to neurotransmission. Roles circled in
red indicate either agonists or antagonists associated with
neuropathy AEs
Table 1 Four pairs of agonists and antagonists of neuropathy-inducing drugs
Target Agonists/antagonists Drugs
adrenergic receptor agonists 3: Tizanidine, Salmeterol, Salmeterol xinafoate
antagonists 7: Ziprasidone, Amiodarone, Amiodarone HCL, Propafenone, Betaxolol, Sotalol, Sotalol HCL
dopamine agonists 4: Bromocriptine, Pergolide, Pramipexole, Ropinirole
antagonists 2: Haloperidol, Ziprasidone
serotonin agonists 4: Almotriptan, Eletriptan, Sumatriptan, Zolmitriptan
antagonists 3: Alosetron, Cyproheptadine, Ziprasidone
hormone receptor agonists 5: Nevirapine, Megestrol, Dexamethasone, Fluticasone, Fluticasone propionate,
antagonists 2: Bicalutamide, Megestrol
modulators 3. Leuprolide, Leuprolide acetate, Taxoxifen
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Our results showed that drug-associated ‘carbon group
molecular entities’ (CHEBI_33582), pnictogen (CHEBI_
33302), chalcogen compounds (CHEBI_33304), and
heterocyclic compounds (CHEBI_5686) were associ-
ated with the highest numbers of AE cases, and these
four groups of chemicals also form a cluster by them-
selves in the heatmap analysis (Fig. 7). The chemicals
in each group are also associated with different types
of neuropathy AEs. For example, in the carbon group
molecular entities, 45 drugs are directly associated
with the top level neuropathy AE, 40 drugs associated
with peripheral neuropathy AE, 6 drugs with neuro-
toxicity AE, and 5 with paresthesia AE. In addition to
the four groups of chemicals with the highest num-
bers of neuropathy-inducing drugs, other groups of
chemicals, including monocyclic, bicyclic, and poly-
cyclic compounds, are also associated with high num-
bers of neuropathy-inducing drugs. The chemical
groups that are the least associated with neuropathy
AEs include copper group entity, ring assembly, and
gold molecular entity chemicals (Fig. 7).
Discussion
The contributions of this article are multiple. First, 215
neuropathy-inducing drugs were manually collected and
curated from different reliable resources. Second,
ODNAE serves as a ontology knowledge base that repre-
sents drug-induced neuropathy AEs and links these AEs
to different sets of entities (e.g., drugs, chemical charac-
teristics, drug targets, drug mechanisms of action, and
biological processes). Third, the knowledge in the ODNAE
knowledge base was analyzed for obtaining scientific in-
sights into drug-associated neuropathy AEs from different
aspects, including related neuropathy AE classifications,
chemical structure patterns, findings from mechanisms of
actions, and the heatmap relations between chemical clas-
sifications and AE types. ODNAE also provides a semantic
platform for further knowledge addition/integration and
advanced analysis. For example, the ODNAE framework
can be extended for other drug and AE studies.
Different from many reference ontologies (e.g., OAE
and DrON) that represent terms and relations among
the terms in a specific domain (e.g., adverse events and
drugs), ODNAE serves as a ontology knowledge base
that reuses reference ontology terms and provides logical
axioms to link different pieces of information such as
neurophathy AEs, drugs, chemical elements of drug ac-
tive ingredients, and mechanisms of action. As a know-
ledge base, ODNAE captures knowledge extracted from
biomedical bench research, clinical practices, and public
health. Owing to the parsable and machine readable
nature of the AE knowledge base, ODNAE supports
neuropathy AE data exchange, data integration, and
automated reasoning and classification.
To demonstrate the advantages of ontology-supported
data integration and classification, we have mined the
ODNAE knowledge base through systematic classifica-
tion and statistical analysis and obtained many scientific
findings from this study. First, we identified the neur-
opathy AE types induced by 215 drugs. Our systematic
classification identified the major drug chemical element
groups (e.g., carbon molecular groups) and their
Fig. 6 SPARQL query of drugs acting as a serotonin agonist. The query was done in Ontobee SPARQL website (http://www.ontobee.org/sparql)
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subgroups that are associated with neuropathy AEs
(Figs. 4 and 7). We have also found an interesting obser-
vation that many agonists and antagonists of the same
targets (e.g., dopamine, serotonin, and sex hormone re-
ceptor) both lead to neuropathy AEs (Fig. 5 and Table 1).
Such observation suggests that these target molecules
require a balanced level in the host, and too high or too
low may lead to neuropathy AEs. We have also
generated a heatmap to further identify the relations be-
tween drug chemical entities and different types of neur-
opathy AEs (Fig. 7).
It is noted that many findings from our ontology
knowledge base analysis have been reported in the litera-
ture [23–31]. For example, agonists and antagonists of
the same targets associated with neuropathy AEs have
been reported previously [23, 24]. Specific chemical
Fig. 7 Heatmap analysis of drug molecular entity-AE relations. Drug molecular entities include 20 DrON terms at the third layer under ChEBI term
‘molecular entity’. Color scheme indicates the numbers of AEs for different groups of drugs: light grey is 0, dark grey is 1, and the rest are ordered
by yellow, orange and red
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structures, which are among the structures found in our
analysis, have been found to be required for the induc-
tion of neuropathy [25–31]. These literature reports in-
deed confirm our analysis results from the usage of the
ontology-based neuropathy-inducing drugs as the only
input data. Given the complete list of the neuropathy-
inducing drugs in our study, our analysis also provides a
comprehensive view of features covered in the ontology.
In addition, our ontology-based strategy generates a se-
mantic framework that brings related information to-
gether in a structured and logical format and supports
knowledge integration and analysis. Such a machine-
readable ODNAE framework is novel and has not been
reported in any neuropathy adverse event studies.
ODNAE also provides a basis for educational learning,
further extension, and interaction with external domains
of knowledge to support integrative neuropathy pharma-
covigilance research.
Beyond the paper’s primary focuses on the data collec-
tion, ontology representation, and ONDAE data analysis
for discovering scientific insights, ODNAE can be fur-
ther used for more case studies in the future. For ex-
ample, the integrated ODNAE knowledge and data can
be used to possibly predict potential neuropathy AEs for
particular drugs based on the structures of the drugs
that have been enriched in our study. Our study found
that over half of the neuropathy-inducing drugs are
organic carbon molecules with special enrichment on
heteroorganic and organic cyclic compounds (Fig. 4). It
is known that some specific chemical structures are
required for the induction of neuropathy [25–31]. For
example, 1,2-diacetylbenzene (1,2-DAB) (but not its
isomer 1,3-DAB), 1,2-Diethylbenzene (1,2-DEB), and
1,2,4-Triethylbenzene (1,2,4-TEB) are able to induce
chromogenic changes and neurotoxicity; and the 1,2-
spaced ethyl (or acetyl) moieties on a benzene ring of
these hydrocarbons have been found to be a critical mo-
lecular arrangement resulting neurotoxic properties [25–
27]. It is interesting that our results show 3 benzene
drug compounds (i.e., fentanyl, sulfasalazine, and
acetylsalicylic acid) and 3 other benzoid drug com-
pounds (i.e., mitoxantrone, fluoxetine, and losartan)
are also associated with neuropathy AEs. Any spe-
cific structures in these and other drug chemical
compounds that may facilitate neuropathy processed
require further analysis. It is likely that structural
similarity analysis combined with biological studies
[28–31] could be conducted among these drugs. To
validate the association between drug structures and
specific neuropathy, observational clinical trials and
laboratory experiments with valid animal models can
be considered. If a structure (e.g., 1,2-spaced ethyl
moieties on a benzene ring) is found to be more
preferentially than others in inducing neuropathy, we
can specifically avoid or modify the structure (with a
balance of efficiency) to increase drug safety.
Another future use of ODNAE is to make ODNAE a
platform to model and represent other information re-
lated to neuropathy-inducing drugs. Chemical character-
istics of drug, drug disposition in humans, and patient
factors could all play a role in the induction of adverse
drug events. For example, drug dosage, environmental
factors, individual patient age, disease, genotype (e.g.,
genetic variations compared to others), and physiological
conditions each plays a critical role in specific drug
neuropathy AEs. These parameters can be linked to
other elements presented in the ODNAE semantic
framework. Such an ontology-based semantic framework
can also be guided by related biological network theor-
ies, including the OneNet Theory of Life [5, 32]. The
ODNAE-based and theory-guided integrative analysis
would be able to identify relations between those factors
and drug-associated neuropathy. Therefore, our work
defines a very important framework for understanding
drug-induced peripheral neuropathy. Ultimately it will
allow us to advance personalized medicine, including the
development of neuroprotective strategies for cancer pa-
tients or patients suffering from neurological disorders
such as diabetic neuropathy.
Our ODNAE will be continuously expanded and com-
puterized to integrate multiple layers of information, in-
cluding chemical characteristics of drugs, biological
receptors and processes at the cellular and molecular
levels, drug disposition in patients, pharmacogenetics,
and population level variables. Drug-associated neur-
opathy AEs are most likely associated with various per-
sonal backgrounds such as age, gender, and genotype.
ODNAE can be expanded to cover these more personal-
ized factors to find trends in neuropathy and better pre-
dict events.
Conclusions
Drugs of diverse pharmacological classes may cause dif-
ferent levels of neuropathy AEs. In this study, 215 drugs
were collected and represented in the Ontology of Drug
Neuropathy Adverse Events (ODNAE). ODNAE serves
as a knowledge base that reuses existing ontologies and
includes logical axioms to represent the relations among
different entities including these 215 drugs, drug-
associated chemical elements, specific neuropathy types,
mechanisms of drug action, and biological processes.
The analyses of logically formed ODNAE information
revealed remarkable scientific insights into drug-
associated neuropathy adverse events. Particularly, our
study found different types of neuropathy AEs induced
by these 215 drugs, major neuropathy-inducing drug
chemical entity groups, the observation of agonists and
antagonists of the same targets that are associated with
Guo et al. Journal of Biomedical Semantics  (2016) 7:29 Page 10 of 12
neuropathy AEs, and specific relations between chemical
groups and types of neuropathy AEs. These findings are
consistent with existing reports, further confirming the
validity of our ontology-based analyses that use the list
of neuropathy-inducing drugs as the only input. Overall,
ODNAE provides a useful platform for integrating and
analyzing currently known information related to drug-
induced neuropathy AEs and is extensible for future new
knowledge representation, analysis and discovery.
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Additional file 1: SPARQL scripts developed for the ODNAE analyses
used in the ODNAE manuscript. (PDF 475 kb)
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